
|Videos|December 28, 2015
Dr. Maurie Markman on Developing Research Into Checkpoint Inhibitors in Ovarian Cancer
Author(s)Maurie Markman, MD
Maurie Markman, MD, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors.
Advertisement
Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors. Markman says only recently have papers been published on checkpoint inhibitors in the treatment of ovarian cancers, marking just how far behind research is on the topic compared to other cancers.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Multimodal AI Outperforms Oncotype DX in Predicting Late Breast Cancer Recurrence
2
T-DXd Benefit Consistent Across Subgroups in High-Risk HER2+ Breast Cancer
3
Sacituzumab Govitecan Improves QOL in Untreated Advanced TNBC
4
T-DXd Plus Pertuzumab Yields Favorable Benefit Over SOC in HER2+ Breast Cancer
5









































